New cocktail of cancer drugs aims to outsmart relapsed myeloma
NCT ID NCT04643002
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This umbrella trial tests the drug isatuximab (Sarclisa) combined with several newer agents, with or without dexamethasone, in adults whose multiple myeloma has returned or stopped responding to at least two prior treatments. About 258 participants will be assigned to different substudies to find the safest and most effective combinations. The goal is to improve response rates and offer more options for this hard-to-treat blood cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- isatuximab (Sarclisa) combined with dexamethasone, pomalidomide, belantamab mafodotin, or pegenzileukin
- What this could lead to
- If successful, this could offer new combination treatment options for people with multiple myeloma that has stopped responding to standard therapies.
- What could go wrong
- This is an early-phase trial with small groups testing different drug combos. Many experimental combinations may not work better than existing ones, and side effects could be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLASMA CELL MYELOMA REFRACTORY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Investigational Site Number : 0360001
RECRUITINGRichmond, Victoria, 3121, Australia
-
Investigational Site Number : 0360002
RECRUITINGMelbourne, Victoria, 3065, Australia
-
Investigational Site Number : 0360006
RECRUITINGWollongong, New South Wales, 2500, Australia
-
Investigational Site Number : 2500001
RECRUITINGNantes, 44093, France
-
Investigational Site Number : 2500002
RECRUITINGLille, 59037, France
-
Investigational Site Number : 2500003
RECRUITINGParis, Washington, 75013, France
-
Investigational Site Number : 2500004
RECRUITINGParis, 75015, France
-
Investigational Site Number : 2760006
RECRUITINGFrankfurt, 60590, Germany
-
Investigational Site Number : 2760008
RECRUITINGLübeck, 23562, Germany
-
Investigational Site Number : 3000001
RECRUITINGAthens, 115 28, Greece
-
Investigational Site Number : 3000002
RECRUITINGAthens, 106 76, Greece
-
Investigational Site Number : 3760001
RECRUITINGTel Aviv, 6423906, Israel
-
Investigational Site Number : 3760002
RECRUITINGJerusalem, 9112001, Israel
-
Investigational Site Number : 3760003
RECRUITINGRamat Gan, 5262100, Israel
-
Investigational Site Number : 3800001
RECRUITINGMeldola, Reggio Emilia, 47014, Italy
-
Investigational Site Number : 4100001
RECRUITINGSeoul, Seoul-teukbyeolsi, 03080, South Korea
-
Investigational Site Number : 4100002
RECRUITINGSeoul, Seoul-teukbyeolsi, 06351, South Korea
-
Investigational Site Number : 4100003
RECRUITINGSeoul, Seoul-teukbyeolsi, 06591, South Korea
-
Investigational Site Number : 4100004
RECRUITINGSeoul, Seoul-teukbyeolsi, 03722, South Korea
-
Investigational Site Number : 5780001
RECRUITINGOslo, 0450, Norway
-
Puerto Rico Medical Research Center- Site Number : 8400005
RECRUITINGHato Rey, Puerto Rico, 00917, Puerto Rico
-
Roswell Park Cancer Institute- Site Number : 8400008
RECRUITINGBuffalo, New York, 14263, United States
-
The Ohio State University- Site Number : 8400012
RECRUITINGColumbus, Ohio, 43210, United States
-
University of Illinois-Chicago - College of Medicine- Site Number : 8400007
COMPLETEDChicago, Illinois, 60612, United States
-
University of Michigan Health System - Ann Arbor- Site Number : 8400004
RECRUITINGAnn Arbor, Michigan, 48109, United States
-
Winship Cancer Institute of Emory University- Site Number : 8400010
RECRUITINGAtlanta, Georgia, 30322, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can adding selinexor to standard therapy extend remission in Hard-to-Treat myeloma?
- Can a new drug combo outsmart Hard-to-Treat myeloma?
- Engineered immune cells take on Hard-to-Treat myeloma
- Home infusion for myeloma drug passes early safety check
- New hope for multiple myeloma: phase 3 trial launches
- New CAR T-Cell therapy targets Hard-to-Treat myeloma